Publications by authors named "Gabriele Piesco"
Article Synopsis
- When patients with metastatic melanoma do not respond to PD-1 inhibitors, ipilimumab may be a viable second-line treatment option in the absence of clinical trials.
- A study of 44 patients who received ipilimumab showed significant differences in overall survival based on genetic mutations (BRAF, NRAS) and the presence of brain metastases, with wildtype patients having the best survival rate.
- The findings suggest that ipilimumab remains an effective therapy especially for those without brain metastases, highlighting the importance of genetic profile in treatment outcome.
Article Synopsis
- Immunotherapy using anti-PD-1 antibodies has improved outcomes for advanced melanoma patients, but resistance to treatment is common.
- This study analyzed the efficacy and safety of a weekly carboplatin plus paclitaxel (wCP) chemotherapy regimen in 30 patients who previously underwent anti-PD-1 treatment.
- Key findings showed a median progression-free survival of 3.25 months and overall survival of 7.69 months, with notable factors influencing outcomes including LDH levels and tumor characteristics.
Background: Stage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit in the adjuvant setting for the delay of recurrence in stage III melanoma patients. Hyperprogression disease was observed as a possible adverse response to immunotherapy in the metastatic setting, suggesting that some patients could face additional risk of progression with ICIs, although no consensus was found for the correct definition of this event.
View Article and Find Full Text PDF(1) Mucosal melanoma (MM) is a rare tumor, accounting for about 1% of all diagnosed melanomas. The etiology and pathogenesis of this tumor are unknown. It is characterized by an aggressive phenotype with poor prognosis and a low response rate to approved treatments.
View Article and Find Full Text PDFMedication-related osteonecrosis of the jaw (MRONJ) is an adverse event associated with antiresorptive and antiangiogenic drugs. The use of these drugs in the treatment of cancer patients with bone metastasis is necessary and standardized in the literature. A multidisciplinary approach for the patient's management is strongly recommended.
View Article and Find Full Text PDFBackground: During epithelial-to-mesenchymal transition, cancer cells lose adhesion capacity gaining migratory properties. The role of the process on prognosis has been evaluated in 50 cases of laryngeal carcinoma.
Methods: E-cadherin, N-cadherin, β-catenin, α-catenin, γ-catenin, caveolin-1, and vimentin immunohistochemical expression were evaluated using a double score based on staining intensity and cellular localization.
Introduction: We describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995.
Methods: A systematic search was performed to identify all articles describing patients with medullary renal cancer until February 2013. Survivals were estimated using Kaplan-Meier method with 95% confidence intervals and compared across the groups using the log-rank test.